Navigation Links
ADVENTRX to Present ANX-201 Preclinical Data at Keystone Symposia HIV Pathogenesis Conference
Date:1/31/2008

SAN DIEGO, Jan. 31 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: ANX), announced today that data from preclinical studies of ANX-201, the Company's broad spectrum antiviral product candidate, has been accepted for presentation at the Keystone Symposia HIV Pathogenesis Conference, which takes place March 27-April 1, 2008 in Banff, Alberta. The HIV Pathogenesis Conference is part of the Keystone Symposia Global Health Series, which is supported by the Bill & Melinda Gates Foundation.

The poster presentation entitled "The pyrophosphate analogue thiophosphonoformic acid confers a favorable HIV resistance profile," is scheduled to be presented on March 30, 2008. The presentation will highlight results of in vitro infectivity assays that demonstrate a unique resistance profile for ANX-201 that suggests suppression of resistance to nucleoside reverse transcriptase inhibitors (NRTIs), a commonly used class of drugs. The potential clinical benefit of ANX-201 when used as part of combination therapy with NRTIs in resistant HIV-infected patients will also be discussed.

About ANX-201

ANX-201 (thiophosphonoformic acid) is a pyrophosphate analog and member of a new class of reverse transcriptase inhibitor (RTI) for treatment of resistant HIV-infected patients. ANX-201 has shown activity against HIV drug-resistant clinical isolates in preclinical studies. The resistance profile of ANX-201 is unique among approved RTIs and has been shown to resensitize NRTI-resistant viruses. In preclinical studies, antiretroviral activity of ANX-201 has demonstrated synergistic activity with NRTIs suggesting potential clinical benefits of combination therapy. In other preclinical studies, ANX-201 has shown broad-spectrum antiviral activity against HIV-1, HIV-2, human and avian influenza viruses, and herpes simplex viruses 1 and 2 (HSV-1 and HSV-2).

About ADVENTRX Pharmaceuticals

ADVENTRX Pharmaceuticals is a biopharmaceutical research and development company focused on commercializing proprietary product candidates for the treatment of cancer and infectious diseases. The Company seeks to improve the performance and safety of existing treatments by addressing significant problems, such as drug metabolism and bioavailability, excessive toxicity and treatment resistance. More information can be found on ADVENTRX's web site at http://www.adventrx.com.

Forward Looking Statement

ADVENTRX cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks and assumptions that, if they materialize or do not prove to be accurate, could cause ADVENTRX's results to differ materially from historical results or those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the validity of research results; the risk that preclinical results are not indicative of the success of subsequent clinical trials and that products will not perform as preclinical data suggests or as otherwise anticipated; unexpected adverse side effects or inadequate therapeutic efficacy of ADVENTRX's product candidates and other uncertainties inherent in the drug development process; the timing and success of clinical trials; difficulties or delays in developing, testing, manufacturing, and obtaining regulatory approval for ADVENTRX's product candidates; the risk that ADVENTRX will be unable to raise sufficient capital to fund the projects necessary to meet its anticipated or stated goals and milestones; and other risks and uncertainties more fully described in ADVENTRX's press releases and public filings with the Securities and Exchange Commission. ADVENTRX's public filings with the Securities and Exchange Commission are available at http://www.sec.gov.

You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date when made. ADVENTRX does not intend to update any forward-looking statement set forth in this press release to reflect events or circumstances arising after the date on which it was made.


'/>"/>
SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
2. ADVENTRX Announces Completion of Patient Enrollment in ANX-530 Marketing-Enabling Clinical Study
3. ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study
4. ADVENTRX Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of CoFactor(R) for the Treatment of Advanced Breast Cancer
5. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
6. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
7. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
8. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
9. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
10. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
11. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... CITY, Calif. , Feb. 4, 2016 /PRNewswire/ ... "Company") today announced it has entered into a ... Exchange Commission (SEC) fully resolving the SEC,s investigation ... Act (FCPA).  Under the terms of the settlement ... of $12.8 million, including disgorgement, pre-judgment interest and ...
(Date:2/4/2016)... Global Immunology Market to 2022 - ... market growth Summary Immune-mediated inflammatory diseases ... that affect 5–7% of western populations. Although they ... and key patient demographics, they are pathophysiologically linked, ... an inappropriate immune response. Generally, disease-modifying anti-rheumatic drugs, ...
(Date:2/4/2016)... 4, 2016  Aethlon Medical, Inc. (Nasdaq: ... devices to treat life-threatening diseases, today announced results ... December 31, 2015. --> ... forth in our last quarterly call, we strategically ... long-term objective to establish the Aethlon Hemopurifier® as ...
Breaking Medicine Technology:
(Date:2/6/2016)... CA (PRWEB) , ... February 06, 2016 , ... US ... Ultimate Coaching Conference (YUCC) . This event brings together top non-profit leaders, ultimate organizations, ... Equity and Girls Ultimate”. Valerio Iani, Bay Area Disc Program Director of Youth and ...
(Date:2/6/2016)... ... February 06, 2016 , ... Research has ... helps to reduce the frequency and level of relapse. , At ... Identity and Purpose,” will explore the critical tasks of the recovery phase and ...
(Date:2/5/2016)... Ontario (PRWEB) , ... February 05, 2016 , ... ... announced the availability of the company's lighter, sleeker next generation LYNX VR Indoor ... plant. , Improvements in design and manufacturing not only reduce the weight ...
(Date:2/5/2016)... ... February 05, 2016 , ... The event is being ... Block Event Center in Minneapolis, Minn. Triumph Over Parkinson’s will fund nearly $100,000 for ... of Schneiderman’s Furniture, lives with Parkinson’s disease and is the architect of this informative ...
(Date:2/5/2016)... ... February 05, 2016 , ... Looking for a last-minute Valentine’s ... the tips of your toes. Foot massage, whether administered by a professional masseuse or ... relaxation. The American Board of Multiple Specialties in Podiatry (ABMSP) has taken ...
Breaking Medicine News(10 mins):